Shares of NovoCure Ltd. (NASDAQ:NVCR) shot up 12.5% during mid-day trading on Monday . The company traded as high as $8.51 and last traded at $8.46, with a volume of 566,982 shares changing hands. The stock had previously closed at $7.52.

A number of research firms have recently issued reports on NVCR. Wedbush restated an “outperform” rating and issued a $30.00 target price on shares of NovoCure in a report on Tuesday, April 5th. Zacks Investment Research lowered NovoCure from a “hold” rating to a “sell” rating in a report on Friday, May 13th. Barclays PLC reduced their target price on NovoCure from $12.00 to $9.00 and set an “underweight” rating for the company in a report on Friday, July 29th. Deutsche Bank AG reduced their target price on NovoCure from $28.00 to $16.00 and set a “hold” rating for the company in a report on Friday, July 29th. Finally, JMP Securities reduced their target price on NovoCure from $43.00 to $34.00 and set a “market outperform” rating for the company in a report on Friday, July 29th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. NovoCure has an average rating of “Hold” and an average price target of $21.43.

The company’s market cap is $671.61 million. The firm has a 50-day moving average price of $11.00 and a 200-day moving average price of $12.48.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, July 28th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.11. The company had revenue of $17.90 million for the quarter, compared to analyst estimates of $15.90 million. On average, analysts predict that NovoCure Ltd. will post ($1.80) EPS for the current fiscal year.

In other NovoCure news, COO Michael J. Ambrogi sold 20,000 shares of NovoCure stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total transaction of $244,800.00. Following the completion of the sale, the chief operating officer now owns 324,084 shares of the company’s stock, valued at approximately $3,966,788.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

A hedge fund recently bought a new stake in NovoCure stock. Morgan Stanley bought a new position in NovoCure Ltd. (NASDAQ:NVCR) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 430,177 shares of the company’s stock, valued at approximately $9,619,000. Morgan Stanley owned about 0.51% of NovoCure as of its most recent SEC filing.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.